|
- Preeclampsia risk prediction from prenatal cell-free DNA screening - Nature
The placenta investigated preeclampsia prediction during early pregnancy using has a well-defined role in the developmental origins of preeclampsia9–11 circulating cfRNA, long-molecule cfDNA
- Non-invasive prediction of preeclampsia using the maternal plasma cell . . .
Background: Preeclampsia (PE) is a pregnancy complication defined by new onset hypertension and proteinuria or other maternal organ damage after 20 weeks of gestation Although non-invasive prenatal testing (NIPT) has been widely used to detect fetal chromosomal abnormalities during pregnancy, its
- New blood test accurately predicts preeclampsia
The samples were collected between 2017-2023 The researchers found that their approach, which uses signals stored within circulating cell-free DNA sequence data, had 80% sensitivity at predicting whether a pregnant individual would experience preterm preeclampsia or not
- Preeclampsia - Can Cell-free Fetal DNA Predict Preeclampsia Before . . .
In this study, researchers investigated if prenatal cell-free DNA screening could be used to predict preeclampsia risk in early pregnancy Researchers used blood specimens drawn for NIPT from around 12 weeks gestation Samples were collected from over 1,000 pregnant patients between 2017 and 2023
- Improving early detection of preeclampsia in prenatal care through . . .
The recent study by Khalil et al1 presents an innovative approach using an artificial neural network model that integrates patient clinical data and cell-free DNA markers from noninvasive prenatal screening to predict preeclampsia early in pregnancy This predictive model demonstrates the potential of artificial intelligence (AI) to improve prenatal care through early identification of high
- The role of cell-free DNA biomarkers and patient data in the early . . .
The primary objective of this study was to evaluate the performance of artificial neural network models for the prediction of preterm preeclampsia (<37 weeks’ gestation) using patient characteristics available at the first antenatal visit and data from prenatal cell-free DNA screening Secondary outcomes were prediction of early-onset preeclampsia (<34 weeks’ gestation) and term
- Maternal cell-free DNA in early pregnancy for preeclampsia screening: a . . .
Purpose To quantify the separation between maternal blood cell-free (cf)DNA markers in preeclampsia and unaffected pregnancies and compare with existing markers This approach has not been used in previous studies Methods Comprehensive systematic literature search of PubMed to identify studies measuring total cfDNA, fetal cf(f)DNA or the fetal fraction (FF) in pregnant women Included
- Early Prediction of Preeclampsia via Liquid Biopsy
A study published in Nature Medicine has demonstrated that prenatal cell-free DNA (cfDNA) sequencing can predict preeclampsia risk months before clinical onset, offering a non-invasive approach to early detection The researchers developed a computational framework – preeclampsia early assessment of risk from liquid biopsy (PEARL) – which analyzes nucleosome accessibility in cfDNA to
|
|
|